Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Cyclacel Pharmaceuticals Inc    CYCC   US23254L3069

 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/18/2015 05/19/2015 05/20/2015 05/21/2015 05/22/2015 Date
0.775(c) 0.74(c) 0.84(c) 0.8187(c) 0.8301 Last
231 590 125 349 780 834 264 445 67 271 Volume
-4.32% -4.52% +13.51% -2.54% +1.39% Change
More quotes
Financials ($)
Sales 2015 -
EBIT 2015 -31,9 M
Net income 2015 -28,9 M
Debt 2015 -
Yield 2015 -
Sales 2016 -
EBIT 2016 -35,1 M
Net income 2016 -35,1 M
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 0
Capi. / Sales 2016 0
Capitalization 28,2 M
More Financials
Company
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company.It engages in developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases.Its most advance product candidate, is the subject of SEAMLESS, a phase 3 trail being... 
More about the company
Latest news on CYCLACEL PHARMACEUTICALS I
05/13 CYCLACEL PHARMACEUTICALS : Reports First Quarter 2015 Financial Results
05/12 CYCLACEL PHARMACEUTICALS : Management's Discussion and Analysis of Financial Con..
05/12 CYCLACEL PHARMACEUTICALS : Results of Operations and Financial Condition, Financ..
05/12 Cyclacel Pharmaceuticals Reports First Quarter 2015 Financial Results
05/05 Cyclacel Pharmaceuticals to Release First Quarter 2015 Financial Results
05/05 CYCLACEL PHARMACEUTICALS : to Release First Quarter 2015 Financial Results
04/20 CYCLACEL PHARMACEUTICALS : Second-Generation CDK2/9 Inhibitor, CYC065, Demonstra..
04/20 Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeut..
More news
Sector news : Bio Therapeutic Drugs
11:28a SYNAGEVA BIOPHARMA : SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investiga..
07:04a BLUEBIRD BIO : Announces Participation at the Jefferies 2015 Global Healthcare C..
05/21 ABBVIE : specifies breakdown of $21 billion Pharmacyclics deal
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
05/13 Cyclacel Pharma revenues up 25% in Q1
05/12 Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q1 2015 Results - Earn..
05/12 Cyclacel Pharmaceuticals beats by $0.06
04/15 Midday Gainers / Losers
03/25 Cyclacel Pharma ups revenues 55% in FY14


Comments 
Advertisement
Chart CYCLACEL PHARMACEUTICALS I
Duration : Period :
Cyclacel Pharmaceuticals I Technical Analysis Chart | CYCC | US23254L3069 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions